Pharma Focus Asia

BioHarvest Sciences Invests US$5.5 million (₪20.2 million) to Open New Facility in Yavne, Israel

Introduction:

BioHarvest Sciences plans to invest US$5.5 million (₪20.2 million) to open new campus for botanical synthesis CDMO and expansion of manufacturing capacity in Yavne, Israel.

Features: 

The project entails the construction of an 80,000 square ft. facility featuring 12 cutting-edge GMP clean rooms. Alongside these industry-leading clean rooms, the facility will include laboratories, offices, and extra space to accommodate a 50-ton manufacturing facility.

This new manufacturing facility will employ upgraded equipment and technologies marking the second generation of the botanical synthesis manufacturing process. This advancement is geared towards enhancing production yields and operational efficiencies even further.

Moreover, the facility will offer a comprehensive end-to-end botanical synthesis development and manufacturing service, all under one roof. The successful implementation of these new technologies is expected to inform the design of a third-generation production facility, projected to be constructed in the USA with a capacity of 150 tons.

In the future, this campus will serve as the hub for all research and development activities, with plans for an additional manufacturing facility scheduled for 2025.

Specifications:

Name       BioHarvest Sciences 
Type         New Construction
Budget    US$5.5 million (₪20.2 million)

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference